Winning PTAB Args Should Be OK For Court, Fed. Circ. Hears

Law360 (February 25, 2019, 6:49 PM EST) -- Warning of high drug prices and a destabilization of America Invents Act reviews, the generic drug industry’s top trade group urged the Federal Circuit on Friday not to adopt the view that patent challengers successful in AIA review can't reuse their arguments in district court.

The Association for Accessible Medicines filed an amicus brief that took direct aim at a position Johnson & Johnson unit Janssen Biotech Inc. has argued in a case against generics makers over a patent on the prostate cancer drug Zytiga.

AAM said Janssen’s interpretation of the law, which has been backed by the U.S. Patent and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!